Related Experiment Video
Updated: Jul 13, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects
1Department of Anatomy and Cell Biology, College of Medicine, The University of Iowa, Iowa City 52242, USA.
Insights
Reactive oxygen species contribute to heart damage, including from ischemia/reperfusion and hypertrophy. Gene therapy shows promise for treating these conditions, but requires further development for clinical use.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Heart and vascular diseases are leading causes of morbidity and mortality globally.
- Reactive oxygen species (ROS) are implicated in myocardial damage, cardiac hypertrophy, and heart failure progression.
- Advances in genomic data and gene manipulation technologies offer new avenues for research.
Purpose of the Study:
- To explore the role of reactive oxygen species in myocardial pathophysiology.
- To investigate the potential of gene therapy in understanding and treating ROS-mediated heart damage.
- To assess the current status and future prospects of gene therapy for cardiac disorders.
Main Methods:
- Review of experimental models and genomic data related to ROS and antioxidant systems.
- Application of gene therapeutic methods to study ROS-mediated myocardial damage.
- Analysis of genetic modulation of ROS and antioxidant pathways.
Main Results:
- Evidence links reactive oxygen species to ischemia/reperfusion injury, cardiac hypertrophy, and failure.
- Genomic data reveals genetic control over ROS and antioxidant defenses.
- Gene therapy tools are being developed to investigate and potentially treat ROS-induced cardiac damage.
Conclusions:
- Reactive oxygen species play a significant role in the development and progression of heart disease.
- Gene therapy presents a promising experimental approach for addressing ROS-mediated myocardial damage.
- Further research into pathophysiology, gene delivery, and therapeutic strategies is crucial for clinical translation.
Abstract:
Heart and vascular diseases continue to rank among the most frequent and devastating disorders to affect adults in many parts of the world. Increasing evidence from a variety of experimental models indicates that reactive oxygen species can play a key role in the development of myocardial damage from ischemia/reperfusion, the development of cardiac hypertrophy, and the transition of hypertrophy to cardiac failure. The recent dramatic increase in availability of genomic data has included information on the genetic modulation of reactive oxygen species and the antioxidant systems that normally prevent damage from these radicals. Nearly simultaneously, progressively more sophisticated and powerful methods for altering the genetic complement of selected tissues and cells have permitted application of gene therapeutic methods to understand better the pathophysiology of reactive oxygen species-mediated myocardial damage and to attenuate or treat that damage. Although exciting and promising, gene therapy approaches to these common disorders are still in the experimental and developmental stages. Improved understanding of pathophysiology, better gene delivery systems, and specific gene therapeutic strategies will be needed before gene therapy of oxyradical-mediated myocardial damage becomes a clinical reality.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:30Coronary Artery Disease I: Introduction